Skip to Main Content

Phase 1 dose escalation: patients enrolled in parallel to one of up to seven dose groups Phase 2 dose expansion: single group, enrolled after Phase 1 dose escalation completed

Conditions

Prostate

Phase I-II

What is the purpose of this trial?

This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 portion of the study will determine the recommended dose of 177Lu-PSMA-R2 for radio-ligand therapy (RLT) of mCRPC, and the Phase 2 portion will expand into approximately 60 patients documenting the preliminary activity (anti-tumor response) of repeated treatments administered, continuing safety assessments and collecting QoL data.

  • Trial with
    Advanced Accelerator Applications International SA
  • Start Date
    09/02/2019
  • End Date
    12/31/2022
Trial Image

For more information about this study, contact:

Matthew Piscatelli

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/05/2019
  • Study HIC
    #2000022743